are of the funds available to be distributed  to each person who files such a claim.

The second option is available for those who have additional purchase information and requires a claimant to not only certify their purchase but  provide the estimated total you paid out of pocket. 

 This option may be more appropriate for you if you paid a significant amount out-of-pocket for these purchases,  the claim website states.

Those who file the second option will have their share  calculated based on the amount you paid, from the funds available to be distributed from the Settlements where you are an eligible claimant. 

 It is possible your payment amount will be higher than the equal share you would receive by selecting Claim Option 1, and will not be less than if you choose Claim Option 1,  the website notes.

Claims can be filed here.

What else to know

It follows three separate lawsuits filed by Raoul and a coalition of states against nearly 50 large generic drug manufacturers  alleging they engaged in a broad, coordinated and systematic campaign to conspire with each other to fix prices, allocate markets and rig bids for hundreds of different generic drugs.  The drugs include statins, ace inhibitors, beta blockers, antibiotics, anti-depressants, contraceptives and non-steroidal anti-inflammatory drugs used to treat everything from from basic infections to diabetes, cancer, epilepsy, multiple sclerosis, HIV, ADHD and more.

According to Raoul, in some instances, the coordinated price increases were over 1,000%.

 These lawsuits allege multiple conspiracies in which executives of competing companies would negotiate illegal agreements during industry dinners, trade shows and customer conferences. They also communicated via frequent telephone calls, emails and text messages, where they discussed allocating customers and coordinating price increases on the products they had in common. Throughout these conspiracies, defendants used terms like  fair share,   playing fair  and  rules of engagement  to describe how they unlawfully discouraged competition, raised prices and enforced an ingrained culture of collusion.

Already, settlements have been agreed to with drugmakers Glenmark, Lannett, Bausch, Apotex and Heritage totaling approximately $96.5 million.

The state said it is preparing for an anticipated trial in 2027.